Dementia Discovery Fund invests in Gen2 Neuroscience Ltd
Gen2 is a start-up drug discovery company seeking to develop drugs that target toxic tau species that cause pathology in dementia, thereby slowing disease progression. London and Boston, 3 June 2016 - The Dementia Discovery Fund, managed by SV Life Sciences, is an innovative global investment fund launched in October 2015 to develop disease modifying drugs for dementia, announces an investment in new drug discovery company Gen2 Neuroscience Ltd.
LifeSci Advisors Announces Comprehensive Action Plan to Advance Gender Diversity in the Life Sciences Industry
NEW YORK, April 15, 2016 (GLOBE NEWSWIRE) -- LifeSci Advisors, a leading life sciences-focused investor relations consultancy, announced today a comprehensive plan to address the lack of gender diversity in the life sciences industry. The company has partnered with pioneering organizations Women in Bio and Girls Inc. of New York City to provide mentorship and advancement programs for women and girls in the STEM (science, technology, engineering, and math) fields, created an advisory board of ...
Michael Balmuth Joins SV Life Sciences as Partner Firm Adds Deep Healthcare IT Experience to Healthcare Services Team BOSTON, MA; SAN FRANCISCO CA; LONDON, UK (July 8, 2014): SV Life Sciences ("SVLS"), a leading, international life sciences venture capital firm, today announced the appointment of Michael Balmuth as Partner. Mr. Balmuth joins SVLS’ Healthcare Services team, a highly experienced group that looks to partner with accomplished management teams with ...
SV Life Sciences Appoints Three New Venture Partners
Firm Adds Significantly to Strength of Biotech Investment Team BOSTON, MA, SAN FRANCISCO, CA, LONDON, UK (June 2, 2014): SV Life Sciences ("SVLS"), a leading international life sciences venture capital firm, today announced the appointments of Dan Burgess, Dr. Ed Mascioli and Dr. Michael Mendelsohn as new venture partners. All three new venture partners will join SVLS’ biotechnology investment team, a highly experienced group investing in truly innovative ...
SV Life Sciences Announces Important Senior Leadership Promotions
SV Life Sciences Announces Important Senior Leadership Promotions BOSTON, MA, SAN FRANCISCO, CA, LONDON, UK (January 13, 2014): SV Life Sciences ("SVLS"), a leading international life sciences venture capital firm, today announced the appointments of Eugene Hill as Chairman, Paul LaViolette as Managing Partner and Chief Operating Officer, Tom Flynn as Managing Partner and Hamish Cameron as Operating Partner.
In the UK, SV Life Sciences Advisers LLP (registered in England OC 308830, VAT 852 5150 39) is authorised and regulated by the Financial Conduct Authority ('FCA'). It is entered into the FCA's register and with registration number 409123. The registered office is 71 Kingsway, London, WC2B 6ST.